Arca
Skip to content
Tools
Tools

CD52: CAMPATH-1 antigen

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

May play a role in carrying and orienting carbohydrate, as well as having a more specific role.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD52, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody

Approved1

  • Alemtuzumab

Phase 30

    Phase 21

    • Alemtuzumab beta

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      AlemtuzumabApprovedSanofiAntibodyInhibitorCAMPATH-1 antigen inhibitor59Boxed warning
      Alemtuzumab betaPhase 2BiogenAntibodyBinding agentCAMPATH-1 antigen binding agent10—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 15 in all, from ClinicalTrials.gov.
      REAL-MS: Observational Database Study of AHSCT and MS TherapiesAlemtuzumab—RecruitingImperial College London2026-10-27
      Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseAlemtuzumabPhase 2RecruitingSt. Jude Children's Research Hospital2026-06-01
      Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsAlemtuzumab, Alemtuzumab betaPhase 1 / Phase 2RecruitingNational Heart, Lung, and Blood Institute (NHLBI)2026-05-20
      Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)AlemtuzumabPhase 2RecruitingPaul Szabolcs2025-12-16
      Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationAlemtuzumabPhase 2RecruitingHannah Choe, MD2025-11-25
      131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)AlemtuzumabPhase 1RecruitingColumbia University2025-06-11
      Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyAlemtuzumabPhase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)2025-05-07
      Allo HSCT for High Risk HemoglobinopathiesAlemtuzumabPhase 2RecruitingMasonic Cancer Center, University of Minnesota2025-03-12
      A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesAlemtuzumab beta—Active, not recruitingBiogen2023-01-18
      Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaAlemtuzumab betaPhase 1 / Phase 2Active, not recruitingNational Heart, Lung, and Blood Institute (NHLBI)2022-05-03
      T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasAlemtuzumab betaPhase 1 / Phase 2RecruitingPaul Szabolcs2018-08-31
      Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersAlemtuzumab betaPhase 2RecruitingMasonic Cancer Center, University of Minnesota2018-07-09
      Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSAlemtuzumab betaPhase 4Active, not recruitingThe Cleveland Clinic2018-05-24
      Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant FailureAlemtuzumab betaPhase 2Active, not recruitingNational Heart, Lung, and Blood Institute (NHLBI)2014-04-07
      CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell TransplantationAlemtuzumab betaPhase 1 / Phase 2Active, not recruitingDiane George2013-10-21

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Autoimmune disorder of central nervous system
      0.36
      Mature T-cell and NK-cell non-Hodgkin lymphoma
      0.34
      Type 1 diabetes mellitus
      0.34
      Hemoglobinopathy
      0.22
      Inborn errors of metabolism
      0.21
      Immunodeficiency disease
      0.21

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1912, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P31358, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.